Figures & data
Figure 1. Time course of seizure scale (stage) of KA-induced seizures. Values represent means ± SEM.
Figure 2. Effects of s.c. administration of vehicle or KA on eGFP fluorescence in (A-a∼g) the LC, (B-a∼g) the NTS, (C-a∼g) the VLM, and (D-a∼g) the AM. Sections (A-a, B-a, C-a, D-a) were obtained from animals 24 h after s.c. administration of vehicle. Scale bars = 200 μm.
Figure 3. Time course of eGFP fluorescence in the LC after s.c. administration of vehicle or KA. **p < 0.01, *p < 0.05 compared with vehicle. Values represent means ± SEM. Number of rats at each point; vehicle (n = 4), 3 h (n = 4), 6 h (n = 5), 24 h (n = 5), 48 h (n = 5), 1 week (n = 6), and 2 weeks (n = 4). Mean density (100% of control) was calculated from the sections obtained from animals 24 h after s.c. administration of vehicle. Statistical significance was determined by one-way ANOVA, following by Holm correction for multiple comparisons (F = 10.781, p < 0.0001).
Figure 4. Effects of s.c. administration of vehicle or KA (12 mg/kg) with pretreatment of vehicle or MK-801 (1 mg/kg) on eGFP fluorescence in the LC. Sections were obtained from (A) vehicle-administered rats pretreated with vehicle or (B) MK-801 (1 mg/kg) and (C) KA-administered rats pretreated with vehicle or (D) MK-801 (1 mg/kg). Scale bar = 50 μm. 4 V, fourth ventricle.
Figure 5. Effect of s.c. administration of vehicle or KA (12 mg/kg) with pretreatment of vehicle or MK-801 (1 mg/kg) on eGFP fluorescence in the LC. **p < 0.01 compared with KA-administered rats pretreated with vehicle. Values represent means ± SEM. Number of rat: vehicle+vehicle (n = 3), MK-801+vehicle (n = 3), vehicle+KA (n = 7), and MK-801+KA (n = 5). Statistical significance was determined by one-way ANOVA, following by Bonferroni correction for multiple comparisons (F = 22.957, p < 0.0001).
Figure 6. Effect of s.c. administration of vehicle (control) or KA (12 mg/kg) on (A, D) eGFP fluorescence and (B, E) TH-immunoreactivity in the LC. (B, E) TH-antibody complexes were visualized as red fluorescence, using Alexa Fluor 546-conjugated secondary antibody. (C, F) Merged view of fluorescence of eGFP and Alex Fluor 546 is seen as yellow. Sections were obtained from (A–C) control or (D–F) KA-treated rats. Boxed areas are enlarged in D, E, and F. Scale bars = 50 μm.
